Location
Areas of Expertise
About Me
Dr. Diana V. Do is a board-certified ophthalmologist and internationally recognized retina specialist at Stanford's Byers Eye Institute. She specializes in the surgical and medical treatment of retinal conditions, including age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinal detachment, macular holes, and epiretinal membranes. Dr. Do incorporates the latest treatment options with a compassionate approach, aiming to provide the highest level of care for each patient.
With over 15 years of experience leading clinical trials, Dr. Do is at the forefront of developing new therapies for retinal vascular diseases and ocular inflammation. She has authored more than 200 publications and has been a principal investigator on numerous studies. Her expertise is recognized nationally, having been selected as a "Top Doctor" in the Bay Area and one of the "100 Top Women in Ophthalmology."
Dr. Do is actively involved in teaching and quality improvement. She serves as Vice Chair for Clinical Affairs and Clinic Chief at Stanford Health Care, where she works to enhance patient experience and access to advanced eye care. Patients benefit from her extensive clinical and surgical experience, as well as her commitment to personalized, state-of-the-art treatment.
Training

Surgical and Medical Retina
2005Johns Hopkins University
Fellowship
Ophthalmology
2003Johns Hopkins University
ResidencyInternal Medicine
2000Massachusetts General Hospital / Harvard Medical School
Residency
Medicine
1999University of California, San Francisco
Medical School
Molecular and Cellular Biology
1995UC Berkeley
Undergraduate
Awards & Honors
Ophthalmology Faculty Teaching Award
2018Stanford University
Honor Award
2016American Society of Retina Specialists
Achievement Award
2008American Academy of Ophthalmology
Heed Clinician-Scientist Fellowship Award
2004Heed Ophthalmic Foundation
Ronald G. Michels Fellowship
2004Ronald G. Michels Foundation
Publications & Press
Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy.
Eye (London, England)•2024Importance of Baseline Fluorescein Angiography for Patients Presenting to Tertiary Uveitis Clinic.
American journal of ophthalmology•2024Risk factors for development of anti-adalimumab antibodies in non-infectious uveitis.
Heliyon•2024
Certifications & Licensure
- Licensed In
- CA, MD
- License Numbers
- C143489, D59856


